Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 8.74 -3.53% -0.32
IRWD closed down 3.53 percent on Friday, October 18, 2019, on 39 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical IRWD trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
20 DMA Support Bullish 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Crossed Above 50 DMA Bullish -3.53%
180 Bullish Setup Bullish Swing Setup -3.53%
NR7 Range Contraction -3.53%
NR7-2 Range Contraction -3.53%
Overbought Stochastic Strength -3.53%

Older signals for IRWD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Medical Specialties Cardiovascular Diseases Central Nervous System Disorders Gastroenterology Peptides European Union Gastrointestinal Diseases Irritable Bowel Syndrome Digestive Diseases Constipation Gastrointestinal Disorders Human Therapeutic Products Ironwood Pharmaceuticals
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.11
52 Week Low 7.91
Average Volume 1,736,480
200-Day Moving Average 11.2191
50-Day Moving Average 9.0141
20-Day Moving Average 8.7078
10-Day Moving Average 8.7335
Average True Range 0.3467
ADX 15.61
+DI 20.392
-DI 23.8979
Chandelier Exit (Long, 3 ATRs ) 8.714900000000001
Chandelier Exit (Short, 3 ATRs ) 8.9501
Upper Bollinger Band 9.3196
Lower Bollinger Band 8.096
Percent B (%b) 0.53
BandWidth 14.05177
MACD Line -0.088
MACD Signal Line -0.1541
MACD Histogram 0.066
Fundamentals Value
Market Cap 1.31 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -8.92
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.27
Resistance 3 (R3) 9.31 9.17 9.18
Resistance 2 (R2) 9.17 9.04 9.15 9.15
Resistance 1 (R1) 8.96 8.96 8.89 8.92 9.12
Pivot Point 8.82 8.82 8.79 8.80 8.82
Support 1 (S1) 8.61 8.69 8.54 8.57 8.36
Support 2 (S2) 8.47 8.61 8.45 8.33
Support 3 (S3) 8.26 8.47 8.30
Support 4 (S4) 8.22